Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

4 Reasons Why You Should Avoid IDEX (IEX) Stock For Now

Published 02/27/2020, 07:07 AM
Updated 07/09/2023, 06:31 AM

IDEX Corporation (NYSE:IEX) seems to have lost its sheen due to challenging end-market conditions and various expenses that are predicted to adversely impact its earnings. Its price performance has been weak lately, while earnings estimates have been lowered too, indicating bearish sentiments for the stock.

The company has a market capitalization of $12.4 billion and a Zacks Rank #4 (Sell) at present. It belongs to the Zacks Manufacturing – General Industrial industry, currently at the bottom 22% (with the rank of 199) of more than 250 Zacks industries. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

We believe that the industry is suffering from global uncertainties, unfavorable movements in foreign currencies, cost escalation — resulting from tariff woes, commodity inflation, high labor costs and freight charges — and other headwinds.

Notably, IDEX delivered weak results in fourth-quarter 2019, with earnings and sales lagging respective estimates by 1.48% and 1.46%. In the past three months, the company’s shares have declined 2.4% against the industry’s growth of 0.2%.





Factors Affecting Investment Appeal

Top-Line Woes: In fourth-quarter 2019, IDEX’s revenues declined 1.3% year over year. Organically, sales were down 2% due to uncertainties related to the soft global economy and weak demand for industrial products globally.

The company is wary about challenging industrial markets and its impact on the results of the first half of 2020. For the year, organic sales are predicted to be down 2% to flat year over year, with a decline of 4-5% expected in the first quarter. Revenues will likely be $2,465-$2,515 million in 2020, suggesting a decline of 1% to growth of 1% from that reported in 2019.

Bottom-Line Woes: The company expects adjusted earnings per share to decline 4% to rise 1% year over year to $5.55-$5.85 in 2020. Various factors are expected to play spoilsport, with 4-cents adverse impact likely from growth investments, 10 cents from tax rate and 6-10 cents from variable compensation.

Forex Woes: Presence in the international markets (contributing 50% to its revenues in 2019) exposed IDEX to geopolitical issues, macroeconomic challenges and unfavorable movements in foreign currencies. In fourth-quarter 2019, forex woes adversely affected the company’s sales by 1%.

Persistence of such issues might pose concerns for IDEX.

Bottom-Line Estimate Trend: The Zacks Consensus Estimate for the company’s earnings has been revised downward in the past 30 days. The consensus estimate for the same is currently pegged at $5.74 per share for 2020 and $6.14 for 2021, reflecting a decline of 4.7% for both years from the 30-day-ago figures.

Also, earnings estimates of $1.32 per share for the first quarter of 2020 suggest a decline of 10.8% from the 30-day-ago figure.

IDEX Corporation Price and Consensus

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

IDEX Corporation price-consensus-chart | IDEX Corporation Quote

IDEX’s Performance Versus Three Other Companies

The company underperformed three companies that belong to the same industry. Three such stocks are Colfax Corporation (NYSE:CFX) , Xylem Inc. (NYSE:XYL) and Tennant Company (NYSE:TNC) , with respective three-month gains of 1.3%, 8.2% and 8%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>



Colfax Corporation (CFX): Free Stock Analysis Report

IDEX Corporation (IEX): Free Stock Analysis Report

Tennant Company (TNC): Free Stock Analysis Report

Xylem Inc. (XYL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.